Sufficient data on the use of the drug trenbolone acetate kits in pregnant women do not have. Asenapine had no teratogenic effects in animal experiments. In these studies, indications and toxicity female embryos were identified.
Newborns whose mothers took antipsychotic drugs during the third trimester of pregnancy are at risk for extrapyramidal symptoms and / or withdrawal symptoms after birth. Obtain reports on the development of agitation, hypertension and hypotension, tremor, somnolence, respiratory distress syndrome and eating disorders in these infants. These complications vary in severity and duration, in some cases, they are self-limiting, in other cases require intensive care and prolong hospitalization. Recommended during pregnancy unless the potential benefit to the patient is much higher than the potential risk to the fetus.
Recorded breeding asenapine or its metabolites in breast milk of women do not have. In studies on rats, asenapine was allocated to the milk during lactation.
Dosing and Administration
Standard doses for treatment of adult patients
Treatment with should begin with a dose of 5 mg twice a day.
The recommended dose of the drug trenbolone acetate kits 5-10 mg twice daily (10-20 mg daily dose).
During short-term controlled clinical studies have not shown an additional clinical effect while taking the drug at a dose of 10 mg twice a day (daily dose 20 mg) compared to the dose of 5 mg twice a day (daily dose 10 mg).
The patient should be periodically inspect to determine the need for maintenance therapy.
The recommended starting dose monotherapy is 10 mg twice a day (daily dose 20 mg). Given the clinical efficacy of the dose can be reduced to 5 mg twice a day (daily dose 10 mg). In combination therapy recommended starting dose is 5 mg twice a day (daily dose 10 mg). The dose may be increased up to 10 mg twice a day (daily dose 20 mg) Subject clinical response and tolerability.
Can not be answered on the basis of the available evidence the question of how long a patient with bipolar disorder should take . In general, patients who responded to treatment, it is recommended to continue receiving the drug and after the acute treatment phase.
The tablet should be removed from the blister immediately before the reception. Hands must be dry. Do not squeeze the tablet through the blister. The blister should not rip or tear. It is necessary to pull the tip of the foil color and remove the tablet gently.
The tablet does not break.
For optimal absorption put the tablet under your tongue until it completely dissolved. The tablet dissolves in saliva within seconds. The tablet does not chew or swallow. After taking the pill do not eat or drink for 10 minutes.
In the combined treatment with other drugs should be taken last.
Use in specific patient populations
The efficacy and safety of the drug in children under 18 years of age has not been studied. There are only limited data on the safety o in adolescents (see. “Pharmacokinetics” section).
The trenbolone acetate kits should be used with caution in elderly patients. Data on the safety and efficacy of the drug in patients aged 65 years and older is limited (see. Section “Pharmacokinetics”).
Patients with impaired renal function
dose adjustment in patients with impaired renal function is not required.
Patients with hepatic impairment
dose adjustment in patients with mild to moderate hepatic impairment is not required. In patients with severe hepatic impairment (class C Child-Pugh) showed a 7-fold increase in AUC of asenapine, it is not recommended to prescribe a in such patients (see. “Pharmacokinetics” section).
Most common adverse reactions trenbolone acetate kits, observed in the treatment with asenapine was sleepy. Adverse reactions observed in clinical and post-marketing studies related to treatment with asenapine, presented in the table below and are classified according to the affected organs and systems of organs and frequency of their occurrence.
In clinical studies, the incidence of extrapyramidal symptoms in the group of patients treated with asenapine, was higher than the placebo group (15.4% and 11.0% respectively). anabolic steroids online pharmacy
online anabolic steroids
online anabolic steroids